Literature DB >> 11815495

Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial.

Curt L Rohlfing1, Hsiao-Mei Wiedmeyer, Randie R Little, Jack D England, Alethea Tennill, David E Goldstein.   

Abstract

OBJECTIVE: To define the relationship between HbA(1c) and plasma glucose (PG) levels in patients with type 1 diabetes using data from the Diabetes Control and Complications Trial (DCCT). RESEARCH DESIGN AND METHODS: The DCCT was a multicenter, randomized clinical trial designed to compare intensive and conventional therapies and their relative effects on the development and progression of diabetic complications in patients with type 1 diabetes. Quarterly HbA(1c) and corresponding seven-point capillary blood glucose profiles (premeal, postmeal, and bedtime) obtained in the DCCT were analyzed to define the relationship between HbA(1c) and PG. Only data from complete profiles with corresponding HbA(1c) were used (n = 26,056). Of the 1,441 subjects who participated in the study, 2 were excluded due to missing data. Mean plasma glucose (MPG) was estimated by multiplying capillary blood glucose by 1.11. Linear regression analysis weighted by the number of observations per subject was used to correlate MPG and HbA(1c).
RESULTS: Linear regression analysis, using MPG and HbA(1c) summarized by patient (n = 1,439), produced a relationship of MPG (mmol/l) = (1.98 . HbA(1c)) - 4.29 or MPG (mg/dl) = (35.6 . HbA(1c)) - 77.3, r = 0.82). Among individual time points, afternoon and evening PG (postlunch, predinner, postdinner, and bedtime) showed higher correlations with HbA(1c) than the morning time points (prebreakfast, postbreakfast, and prelunch).
CONCLUSIONS: We have defined the relationship between HbA(1c) and PG as assessed in the DCCT. Knowing this relationship can help patients with diabetes and their healthcare providers set day-to-day targets for PG to achieve specific HbA(1c) goals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11815495     DOI: 10.2337/diacare.25.2.275

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  226 in total

1.  HbA1c measurement.

Authors:  E S Kilpatrick
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

Review 2.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

3.  Effect of short-term use of a continuous glucose monitoring system with a real-time glucose display and a low glucose alarm on incidence and duration of hypoglycemia in a home setting in type 1 diabetes mellitus.

Authors:  Raymond J Davey; Timothy W Jones; Paul A Fournier
Journal:  J Diabetes Sci Technol       Date:  2010-11-01

4.  Standards of medical care in diabetes--2011.

Authors: 
Journal:  Diabetes Care       Date:  2011-01       Impact factor: 19.112

5.  Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet.

Authors:  Belinda S Lennerz; Anna Barton; Richard K Bernstein; R David Dikeman; Carrie Diulus; Sarah Hallberg; Erinn T Rhodes; Cara B Ebbeling; Eric C Westman; William S Yancy; David S Ludwig
Journal:  Pediatrics       Date:  2018-05-07       Impact factor: 7.124

6.  How should HbA1c measurements be reported?

Authors:  F Gorus; C Mathieu; E Gerlo
Journal:  Diabetologia       Date:  2006-01       Impact factor: 10.122

7.  Changes in dried blood spot Hb A1c with varied postcollection conditions.

Authors:  Orfeu M Buxton; Keith Malarick; Wei Wang; Teresa Seeman
Journal:  Clin Chem       Date:  2009-03-19       Impact factor: 8.327

8.  Markers of glycemic control in the mouse: comparisons of 6-h- and overnight-fasted blood glucoses to Hb A1c.

Authors:  Byoung Geun Han; Chuan-Ming Hao; Elena E Tchekneva; Ying-Ying Wang; Chieh Allen Lee; Benyamin Ebrahim; Raymond C Harris; Timothy S Kern; David H Wasserman; Matthew D Breyer; Zhonghua Qi
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-07-29       Impact factor: 4.310

9.  Improvement of diabetes indices of care by a short pharmaceutical care program.

Authors:  Mertkan Turnacilar; Mesut Sancar; Sule Apikoglu-Rabus; Mehmet Hursitoglu; Fikret Vehbi Izzettin
Journal:  Pharm World Sci       Date:  2009-09-24

10.  Determination of glycated hemoglobin in patients with advanced liver disease.

Authors:  Theresa Lahousen; Karin Hegenbarth; Rottraut Ille; Rainer-W Lipp; Robert Krause; Randie-R Little; Wolfgang-J Schnedl
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.